Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Regeneron Pharmaceuticals Details C5 Strategy, With PNH Data Due Q4 and gMG NDA Under Review

Summary by marketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody already approved for an ultra-rare disease. Executives emphasized a “match the biology” approach—usin

1 Articles

marketbeat.commarketbeat.com
Center

Regeneron Pharmaceuticals Details C5 Strategy, With PNH Data Due Q4 and gMG NDA Under Review

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody already approved for an ultra-rare disease. Executives emphasized a “match the biology” approach—usin

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news on Saturday, April 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Tarrytown icon

Tarrytown

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal